NEW YORK–(BUSINESS WIRE)–#RETA–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) on behalf of Reata stockholders. Our investigation concerns whether Reata has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On December 6, 2021, the U.S. Food and Drug Administration (“FDA”) released a briefing document regarding Reata’s chronic kidney disease drug candidate, bardoxolone methyl. Therein, the FDA stated that the data submitted by Reata did not “demonstrate that bardoxolone is effective in slowing the loss of kidney function in patients with [Alport syndrome].”
On this news, Reata’s stock price fell $29.77 per share, or 37.8%, to close at $48.92 per share on December 6, 2021.
If you purchased or otherwise acquired Reata shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra B. Raymond by email at email@example.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.